NPCE
Neuropace, Inc. Common Stock
stockNASDAQ
the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 12.50 | 2026-11-06 | -54.08% | 2.830 |
| 1M | 12.68 | 2026-10-13 | -54.73% | 1.669 |
| 3M | 14.51 | 2026-08-13 | -60.44% | 1.401 |
| 6M | 15.81 | 2026-05-13 | -63.69% | 1.252 |
| 1Y | 12.81 | 2025-11-13 | -55.19% | 1.338 |
| 2Y | 9.15 | 2024-11-13 | -37.27% | — |
| 5Y | 14.00 | 2021-11-12 | -59.00% | 0.951 |
Neuropace, Inc. Common Stock (NASDAQ:NPCE) stock price today is $5.74, and today's volume is 2,306,182. NPCE is down 52.246% today. The 30 day average volume is 118,267. NPCE market cap is $197.02M with 34.32M shares outstanding.